Therapy for NAFLD Are we getting there? Sanjay Bhagani Royal Free London/UCL
|
|
- Elisabeth Young
- 5 years ago
- Views:
Transcription
1 Therapy for NAFLD Are we getting there? Sanjay Bhagani Royal Free London/UCL
2 What is NAFLD? Non-Alcoholic Fatty Liver Disease Wide disease range from simple steatosis to cirrhosis Steatosis Steatosis/inflammation Fibrosis Cirrhosis Steatosis NASH Cirrhosis 12-40% 15%
3 NAFLD: Potential consequences HCC Kotronen, Arterioscler Thromb Vasc Biol 2008
4 NASH is the Subtype of NAFLD that Primarily Progresses NASH progressive in a sub-set of NAFL patients Stable NAFLD Liver Failure NASH 10-15% Cirrhosis 40-60% 20-30% Death 65-75% 2%) HCC (Annual incidence Stable Ludwig 1980; Diehl 1988; Lee 1989; Powell 1990; Bacon 1994; Matteoni 1999; Angulo 1999; Caldwell 1999; Ponawala 2000; Contos 2001; Ong 2001; Bugianesi 2002; Ratziu 2002; Harrisson 2003; Marchesini 2003; Younossi 2004; Fassio 2004; Sanyal 2004; Ong 2005; Adams 2005; Ong 2006; Rafiq 2008; Stepanova 2010; Younossi 2012.
5 Fibrosis stage is predictive of survival 619 biopsy-proven NAFLD, FU 12.6 yrs 229 biopsy-proven NAFLD, FU 26 yrs F0 F1 F2-F3 F4 Controls F<3 F>2 Cause of death: cardiovascular 38-43%, cancer 19%, cirrhosis 4-8% HCC 1-5% Independent predictors: fibrosis, diabetes, tobacco, statin use Angulo P et al. Gastroenterology 2015 Ekstedt M et al. Hepatology 2015
6 The molecular engine that drives disease progression NASH Metabolic abnormality Apoptosis Inflammation Fibrosis Cirrhosis HCC Hepatic Fat Adapted from Arun Sanyal, NASH Symposium Paris June 2015
7 Appropriate End-points for therapeutics in NAFLD Early phase trials Populations with NASH or at high-risk of NASH Primary end-points based on mechanism of drug tested; e.g. reduction in hepatic fat by MR-Proton Density Fat Fraction, CAP Phase 3 studies Biopsy proven NASH (NAS score >2) with F2+ fibrosis Primary End-point Complete resolution of steatohepatitis and no worsening of fibrosis At least one point improvement in Fibrosis score with no worsening of steatohepatitis
8 Therapeutics for NASH Metabolic abnormalities Cell-stress/apoptosis and inflammation Antifibrotics Gut-Liver axis
9 NASH multiple potential targets Banini & Sanyal, Curr. Opin. Gastroenterol. 2017
10 What works and what doesn t work data to date Diet/exercise 5% weight loss improves steatosis 7% improvement in inflammation >10% for improvement in fibrosis Insulin sensitising agents Glitazones/Metformin?effective in pre-diabetics/t2dm Anti-lipid therapies Fibrates, statins may improve lipids BUT no/little effect on hepatic inflammation/fibrosis Anti-oxidants Vitamin E works (but risk of Prostate cancer??)
11 Other/upcoming agents for metabolic targets
12 Obetichocolic Acid (OCA) OCA) Semisynthetic bile acid analog (6α-ethyl-chenodeoxycholic acid) 100 times more potent than chenodeoxycholic acid in binding farnesoid X receptor Treatment with OCA has been associated with Improved insulin sensitivity Reductions in markers of liver inflammation and fibrosis Reductions in triglyceride levels Dose-related weight loss OCA was generally well tolerated; adverse effects were similar across treatment groups Increases in LDL and reductions in HDL Mudaliar S, et al. Gastroenterology. 2013;145:
13 % of Responders FLINT Phase 2 Trial Design The Farnesoid X Receptor Ligand Obeticholic Acid (OCA) in NASH Treatment (OCA vs. Placebo for 72 Weeks N=283) Fibrosis Improvement & No worsening of Steatohepatitis Lipid Parameters Measured 5 0 ** Total cholesterol LDL HDL Triglycerides % OCA Pla OCA Pla OCA Pla OCA Pla Baseline % Δ Baseline - 72 wks +6* -7* +9* -8* -1* +1* Δ Baseline - 96 wks P la c e bo O be tic holic Ac id Pruritus higher in OCA group (23% vs 6%) 1 dc d OCA Other AEs were similar to placebo and most SAE unrelated to therapy Brent A Neuschwander-Tetri, et al. Lancet
14 FLINT: Primary and Secondary Histological Endpoints 70% 60% 50% 45% 61% % of Patients with Improvement OCA Pbo P= P=0.001 P=0.006 P=0.03 P=0.004 P=0.08 P= % 46% LDL-C increased pruritus 40% 30% 20% 21% 38% 35% 31% 35% 19% 22% 13% 13% 12% 10% 0% Primary Endpoint Steatosis Lobular Inflammation Ballooning Fibrosis NASH resolution Portal Inflammation Neueschwander-Tetri BA et al. Lancet 2014
15 Elafibranor (GFT505): mechanism of action
16 One year elafibranor vs. placebo in NASH 16 Placebo (n = 92) ITT analysis Elafibranor 80 mg (n = 93) Elafibranor 120 mg (n = 89) p (120 mg vs placebo) Primary endpoint* 17 % 23 % 21 % 0,28 Placebo (n = 76) Post hoc analysis in NAS 4 Elafibranor 80 mg (n = 83) Elafibranor 120 mg (n = 75) p (120 mg vs placebo) Primary endpoint* 11 % 20 % 20 % 0,018 *Reversal of NASH without worsening of fibrosis Ratziu et al, Gastroenterology 2016
17
18
19
20 Cell-stress/apoptosis and inflammation inhibitors
21 GS-4997 Alone (Apoptosis Signal-regulating Kinase (ASK- 1) Inhibitor) or in Combination with Simtuzumab Phase II Trial Phase 2, Randomized, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab in NASH and Fibrosis Stages F2-F3 Intervention: Arm A: GS mg QD+SIM 125 mg SQ weekly for 24 wks Arm B: GS mg QD+SIM 125 mg SQ weekly for 24 wks Arm C: SIM 125 mg SQ weekly for 24 weeks NASH with F2-F3 Primary Outcomes: Adverse event of GS-4997 (Treatment-emergent SAE, worsening AST & ALT) Percent who prematurely discontinuation due to AE ClinicalTrials.gov. NCT
22 GS-4997, an inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with Simtuzumab - results Percent of Subjects 100 GS4997 (2 doses) + Sim vs Sim alone 2:2:1:1:1 randomization, Stratified by diabetes NASH, NAS 5, F mg ± SIM 6 mg ± SIM SIM /30 8/27 2/10 11/30 8/27 2/10 Fibrosis Improvement Fibrosis Improvement without NASH Worsening * 3 7 2/27 2/10 1/30 Progression to Cirrhosis Loomba R et al, AASLD 2016
23 CCR2 and CCR5 Promote Obesity-Induced Inflammation and Insulin Resistance Reproduced from Xu et al. Biomolecules 2015;5(3): by the authors; licensee MDPI, Basel, Switzerland. Taken from an open access article distributed under the terms and conditions of the Creative Commons Attribution License ( 11
24 1:1 Randomization 1:1 HEP DART 2015 CENTAUR: NASH with Fibrosis Phase 2b Study Global study 289 subjects enrolled Key eligibility criteria Biopsy diagnosis of NASH with fibrosis Enriched for patients with T2DM High BMI with >1 criteria of metabolic syndrome Bridging fibrosis and/or definite NASH Baseline CVC 150 mg Placebo Primary Analysis (Year 1) CVC 150 mg CVC 150 mg Placebo Final Analysis (Year 2) Primary endpoint 2-point improvement in NAS without worsening of fibrosis) Key secondary endpoint Resolution of NASH without worsening of fibrosis Other endpoints Change in fibrosis stage Collagen morphometry α-sma, CK-18 Validated fibrosis scores Noninvasive imaging and biomarkers Kidney function Screening biopsy Primary endpoint biopsy Final biopsy NCT
25 CENTAUR: primary endpoint not met but key secondary endpoint on fibrosis improvement met Placebo (N=144) 25% 20% 19% 15% 10% 5% CVC (N=145) 16% 25% 20% 15% 10% 5% 6% 8% P< % 20% 0% 2-point Improvement in NAS AND No Worsening of Fibrosis 0% Complete Resolution of NASH AND No Worsening of Fibrosis Improvement in Fibrosis Stage AND No Worsening of NASH PRIMARY ENDPOINT SECONDARY ENDPOINTS Sanyal A et al, AASLD 2016
26 Antifibrotics
27
28
29
30
31 NASH* landscape: Segmentation by company NAFLD Pipeline X Interaction with company in progress Not available for partnering Covered by internal program Declined or MoA not interesting Antifibrotic BOT-191/BiOrion X ZGN-839/Zagfen Glucose metabolism X IVA-337/Inventiva NGM313/NGM Bio X FG-3019/FibroGen GS-0976/Gilead Nimbus NC-101/Naia Semaglutide/Novo ND-L02-s0201/Nitto Denko GR-MD-02/Galectin X MSDC-0602/Octeta KBP-042/Nordic Bioscience Simtuzumab/Gilead DS-102/Afimmune MN-001/MediciNova GRI-0621/GRI Bio PRX-106/Protalix GKT831/GenKyotex GS-4997/Gilead Emricasan/Conatus Cenicriviroc/Allergan/Tobira X Oxidative stress X X Elafibranor/Genfit PXS-4728/BI X MT-3995/Mitsubishi RTU-1096/Sucampo FXR/Allergan/Akarna EDP-305/Enanta INT-767/Intercept LJN452/Novartis/NIBR GS-9674/Gilead Aramchol/Galmed X Volixibat/Shire Obeticholic acid/intercept saroglitazar/zydus A4250/Albireo MGL-3196/Madrigal AZD4076/AZ NGM-282/NGM X X JKB-121/Taiwan J Pharma VK-2809/Viking IMM-124-E/Immuron Solithromycin/Cempra VK-0214/Ligand DRX-065/DeuteRx BMS /BMS TEV-45478/Teva X VLX103/Verlyx Lipid metabolism X IONIS-DGAT2Rx/Ionis X LY /Lilly BMS /BMS DUR-928/Durect NP-201 program/ngm/merck X RYI-018/Ruiyi Phase II Phase IIb Phase IIa Phase I Preclinical LMB-763/Novartis Other Anti-inflammatory UD-014/Ube Bertilimumab/Immune Therapeutics Sources: pipeline databases, company websites, competitive intelligence analysis. Preclinical: only selected projects to reach clinical development in 2016 are shown. More than one mode of action may be applicable for a given drug. *NASH compounds only. Projects with only NAFLD patients are not considered Immunomodulatory Drug/company (MoA) FDA Fast Track for NASH Breakthrough designation
32 Future markets.
33 Targeted therapies for NAFLD A better understanding of the pathaphysiology Biomarker development for prediction of progression, inflammation and fibrosis Imaging/sonographic modalities
34 Acknowledgements Patrick Ingiliz Manolis Tsotchasiz Maud Lemoine Laurent Sefarty Zobair Yaunossi
An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications
REVIEW An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications Naim Alkhouri, M.D.,*, and Andrea Scott, B.S.* Nonalcoholic fatty liver disease (NAFLD)
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationOverview of the Clinical Trial Data on Non-alcoholic Steatohepatitis (NASH)
Overview of the Clinical Trial Data on Non-alcoholic Steatohepatitis (NASH) Brent A. Neuschwander-Tetri, MD, FACP, FACG, AGAF, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology
More informationStudy Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH
Study Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology
More informationNASH UPDATE ON DIAGNOSTICS AND THERAPY. Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine
NASH UPDATE ON DIAGNOSTICS AND THERAPY Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine Conflicts of interest Salaried employee: of VCU Member of Board: McGuire VA Research Institute,
More informationNon-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research
Non-alcoholic fatty liver disease: time to take note and manage Philip Newsome Professor of Hepatology & Director of Centre for Liver Research Disclosures Consultancy, Co-ordinating Investigator roles
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationInvestigating general liver disease/transaminitis
BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive
More informationThe Spectrum of NAFLD. Hepatology Update: The Year in Review Fatty Liver Disease. Hepatology Update: The Year in Review Fatty Liver Disease
Ludwig 1980, Diehl 1988, Lee 1989, Powell 1990, Bacon 1994, Younossi 1997, Matteoni/Younossi 1999, Angulo 1999, Caldwell 1999, Ponawala 2000, Contos 2001, Ong/Younossi 2001, Bugianesi 2002, Ratziu 2002,
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Varun Saxena, MD MAS Gastroenterology and Hepatology Kaiser Permanente South San Francisco Assistant Clinical Professor University of California San Francisco January
More informationEASL International Liver Congress Paris, France 14 April 2018
NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis
More informationFatty Liver, NASH: new diagnostics and new treatments
Fatty Liver, NASH: new diagnostics and new treatments Robert G Gish MD Professor Consultant Stanford University HASLD TP HCMC June 2016 NAFLD: the hepatic manifestation of the metabolic syndrome Obesity
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationOral Testosterone (T) Non Alcoholic Steatohepatitis (NASH)
Oral Testosterone (T) Non Alcoholic Steatohepatitis (NASH) 1 LPCN 1144: Well Positioned for Success Unique Mechanism of Action with Compelling Clinical Signal Targeting Full Spectrum of NASH Pathogenesis
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationInternal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018
Internal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018 Nonalcoholic Fatty Liver Disease (NAFLD) Turns 38-What Have We Learned? Jay D. Horton, M.D. This is to acknowledge
More information2 nd International Workshop on NASH Biomarkers, Washington DC, May 5-6, 2017
Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multi-center Nonalcoholic Steatohepatitis Clinical Trial Michael
More informationINVESTOR PRESENTATION. November 16 th, 2015
INVESTOR PRESENTATION November 16 th, 2015 1 Disclaimer Important information and forward looking statements GENFIT IS A PUBLIC COMPANY LISTED ON EURONEXT PARIS (COMPARTMENT B) STOCK EXCHANGE SINCE APRIL
More informationEvercore ISI Presentation- Madrigal
Evercore ISI Presentation- Madrigal Forward-Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our clinical studies and our research and development
More informationLiver Disease in HIV. Sanjay Bhagani Royal Free Hospital/UCL London
Liver Disease in HIV Sanjay Bhagani Royal Free Hospital/UCL London Disclosures Grants/travel support/speaker fees Abbvie Gilead ViiV Outline Importance of liver disease in HIV Global burden of Viral Hepatitis
More information6/28/2017. Update in NAFLD. Key Points. NAFLD: Epidemiology. US Population: million. NALFD Prevalence 25% 80 million
Update in NAFLD PHILLIP K HENDERSON, DO ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE INSTRUCTOR OF SURGERY, DIVISION OF TRANSPLANT SURGERY UNIVERSITY OF ALABAMA AT BIRMINGHAM
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationGENFIT OVERVIEW. September 2016
2016.09 GENFIT OVERVIEW September 2016 1 Disclaimer Important information and forward looking statements THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. THE INFORMATION
More informationNAFLD 2017 Identifying and managing disease while waiting for a cure
NAFLD 2017 Identifying and managing disease while waiting for a cure A. Sidney Barritt IV, MD, MSCR Associate Professor of Medicine UNC Liver Center High Impact Hepatology 4 November 2017 Disclosures I
More informationWHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF
WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF ctliver@fegato.it Worldwide estimated prevalence of NAFLD distribution of PNPLA3 genotypes 2017-Younussi
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationThe Skinny On Non Alcoholic Fatty Liver Disease
The Skinny On Non Alcoholic Fatty Liver Disease UCSF Advances in Internal Medicine Monika Sarkar, MD, MAS UCSF Division of GI/Hepatology June 24th, 2015 Non Alcoholic Fatty Liver Disease: Outline Pathogenesis
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationRegulatory Updates Veronica Miller, PhD
Regulatory Updates Veronica Miller, PhD Forum for Collaborative Research UC Berkeley SPH PARIS_NASH_2018 2 PARIS NASH 2018 Disclosures Dr. Veronica Miller is an employee of the Forum for Collaborative
More informationLipid and Bile Acids as NAFLD- Related Biomarkers
Lipid and Bile Acids as NAFLD- Related Biomarkers Puneet Puri, MBBS, MD Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University, Richmond, VA 1st International Workshop
More informationNAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationNONALCOHOLIC STEATOHEPATITIS (NASH) - OPPORTUNITY ANALYSIS AND FORECASTS TO EVENT-DRIVEN UPDATE
REFERENCE CODE GDHC034POA PUBLICAT ION DATE MARCH 2014 NONALCOHOLIC STEATOHEPATITIS (NASH) - - EVENT-DRIVEN UPDATE Executive Summary NASH: Key Metrics in Six Major Pharmaceutical Markets 2012 Epidemiology
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationNonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup
REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined
More informationFatty Liver Disease. Mark Thursz. Imperial College
Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were
More informationA pathologist, a radiologist and a hepatologist walked into a bar
A pathologist, a radiologist and a hepatologist walked into a bar Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology Saint Louis
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationLiver biopsy as the gold standard for diagnosis. Pierre BEDOSSA
Liver biopsy as the gold standard for diagnosis Pierre BEDOSSA 1 PATHOLOGY OF NAFLD CONFLICTS OF INTEREST Grants and funding from Genfit, Intercept, Allergan, Inventiva, OWL, Echosens CEO and funding of
More informationNASH PROGRESS IN THE LAST DECADE
PROGRESS IN THE LAST DECADE Mitchell L. Shiffman, MD, FACG Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need A GLOBAL HEALTH PROBLEM Nigeria Australia Spain
More informationDiseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic
Diseases to Watch Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) - Prevalence and Symptoms - Risk Factors and Potential treatments - Target identification for NASH Robert
More informationPHC, Paris, 30th Jan 2017 PATHOLOGY OF NAFLD. Pierre Bedossa. Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE
PHC, Paris, 30th Jan 2017 PATHOLOGY OF NAFLD Pierre Bedossa Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE 1 PATHOLOGY OF NAFLD NAFLD: a chronic liver disease with a wide
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationWhat to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology
What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationGOLDEN-505 STUDY EASL INVESTOR EVENT. Vienna April 24, 2015
GOLDEN-505 STUDY EASL INVESTOR EVENT Vienna April 24, 2015 1 Disclaimer Important Information and Forward Looking Statements GENFIT IS A PUBLIC COMPANY LISTED ON EURONEXT PARIS (COMPARTMENT B) STOCK EXCHANGE
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationGENFIT Overview Focus on GFT505
Apr 2014. v32fi GENFIT Overview Focus on GFT505 April 2014 1 Disclaimer Important Information and Forward Looking Statements GENFIT IS A PUBLIC COMPANY LISTED ON EURONEXT PARIS (COMPARTMENT B) STOCK EXCHANGE
More informationDisclosures. The Typical Therapeutic Pyramid $$$ The NAFLD Umbrella. The Big Question: What are the treatment options for NASH?
Disclosures I have the following relationships to disclose: Ethicon Endo Surgery Inc. Galectin Therapeutics Synageva Biopharma Raptor Pharmaceuticals I will be discussing off label use of medications in
More informationFDA Introductory Remarks Stephanie O. Omokaro, MD
FDA Introductory Remarks Stephanie O. Omokaro, MD Division of Gastroenterology & Inborn Errors Products (DGIEP) Center for Drug Evaluation and Research Office of New Drugs Office of Drug Evaluation III
More information«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationNon-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know
Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
More informationHow to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris
How to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris CLINICAL CASE 1996. 54 years old female Department of Primary CV Prevention
More informationCDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health
CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
More informationGR-MD-02 for Indication of NASH Cirrhosis: NASH-CX Clinical Trial Results
GR-MD-02 for Indication of NASH Cirrhosis: NASH-C Clinical Trial Results Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 1 2018 2017 Galectin
More informationINVESTOR PRESENTATION
2017.04.24 INVESTOR PRESENTATION APRIL 2017 1 Disclaimer Important Information and Forward Looking Statements THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN
More informationSteatotic liver disease
Steatotic liver disease Fatty liver disease Prof. Dr. ANNE HOORENS Non-Neoplastic Liver Pathology December 8th 2018 Working Group of Digestive Pathology Belgian Society of Pathology OUTLINE NAFLD = Non-Alcoholic
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationNAFLD - therapeutic intervention. CP Day Institute of Cellular Medicine Newcastle University UK
NAFLD - therapeutic intervention CP Day Institute of Cellular Medicine Newcastle University UK Therapy for NAFLD Why worry about NAFLD? Management strategy - who to treat? Therapies directed at features
More informationNON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES
NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES Preface Zobair M. Younossi xiii Epidemiology and Natural History of NAFLD and NASH 1 Janus P. Ong and Zobair M. Younossi Understanding
More informationMadrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
Madrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial -- Statistically significantly more patients treated with
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationAdvances in Understanding Hepatic Fibrosis and Chronic Liver Disease
Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease Scott Friedman, M.D. Fishberg Professor of Medicine Dean for Therapeutic Discovery Chief, Division of Liver Diseases Icahn School of
More informationWORLDWIDE EPIDEMIOLOGY OF NASH
WORLDWIDE EPIDEMIOLOGY OF NASH Stefano Bellentani, M.D., Ph.D. Chief of Gastroenterology and Hepatology Service Clinica Santa Chiara Locarno Switzerland & Fondazione Italiana Fegato (FIF), Bassovizza (Trieste),
More informationTherapeutic Approaches to Cirrhotic versus Pre-Cirrhotic NASH
www.alacrita.com Therapeutic Approaches to Cirrhotic versus Pre-Cirrhotic NASH 2nd Annual NASH Summit Europe October 23-24, 2018 Frankfort, Germany Peter G. Traber, MD Partner, Alacrita Consulting Alacrita
More informationNAFLD: ACG Southern Regional Course Nashville, TN. Speaking - None
NAFLD: 2015 Naga Chalasani, MD, FACG David W. Crabb Professor of Medicine Director, Division of GI and Hepatology Indiana University School of Medicine ACG Southern Regional Course Nashville, TN Disclosures
More informationJan vp24.i. GENFIT Overview. January 2014
Jan 2014. vp24.i GENFIT Overview January 2014 1 Disclaimer Forward Looking Statement GENFIT IS A PUBLIC COMPANY LISTED ON NYSE EURONEXT (ALTERNEXT PARIS) STOCK EXCHANGE SINCE 2006. THIS DOCUMENT DOES NOT
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationCompany Overview. September 2018 NASDAQ: MDGL
Company Overview September 2018 NASDAQ: MDGL 1 Forward Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our future financial or business
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationNONALCOHOLIC FATTY LIVER DISEASE
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis
More informationChallenges in the Diagnosis of Steatohepatitis
The Bugaboos of Fatty Liver Disease: Ballooning and Fibrosis Hans Popper Hepatopathology Society Companion Meeting San Antonio, Tx March, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Challenges
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationGENFIT: New data to be presented at 2018 AASLD meeting, ahead of key results expected in 2018 and 2019
GENFIT: New data to be presented at 2018 AASLD meeting, ahead of key results expected in 2018 and 2019 KOL event to be held ahead of expected data release with elafibranor in PBC by end of 2018 (Phase
More informationThe EMA reflection paper on chronic liver disease and its implications for drug development in NASH
The on chronic liver disease and its implications for drug development in NASH Content of the reflection paper and report from stakeholder meeting Elmer Schabel MD No conflict of interest. Content Overview:
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationDefining the gold standard in biomarker validation for NASH
Defining the gold standard in biomarker validation for NASH Arun J Sanyal M.D. Professor of Medicine, Physiology and Molecular Pathology Virginia Commonwealth University School of Medicine Conflicts of
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationTherapeutic targets and the management of NASH
Therapeutic targets and the management of NASH Joo Hyun Sohn, MD. Professor of Medicine, College of Medicine, Hanyang University Division of Gastroenterology and Hepatology Hanyang University Guri Hospital
More informationALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,
Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total
More informationCORPORATE PRESENTATION
NOVEMBER 2018 CORPORATE PRESENTATION November 2018 I. CORPORATE HIGHLIGHTS II. LEADERSHIP IN NASH & PBC APPENDIX 1 Disclaimer Important Information and Forward Looking Statements THIS PRESENTATION HAS
More informationINVESTOR PRESENTATION
SEPTEMBER 2018 INVESTOR PRESENTATION September 2018 I. PIPELINE II. INTRODUCTION TO NASH III. GENFIT ASSETS IN NASH IV. BEYOND NASH V. MOVING FORWARD VI. CORPORATE HIGHLIGHTS 1 Disclaimer Important Information
More informationNAFLD: US GUIDELINES. US Guidelines for NAFLD
NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG
More informationRodman & Renshaw 17 th Annual Global Investment Conference
Rodman & Renshaw 17 th Annual Global Investment Conference September 10, 2015 NASDAQ: GALT www.galectintherapeutics.com 2015 Galectin Therapeutics Inc. Forward-Looking Statements This presentation contains,
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationtage Percent Total & over Total & over Men Women Men Women
Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University
More informationUpdate on Clinical Management
Non-Alcoholic Fatty Liver Disease Update on Clinical Management Lisa J. Yoo, D.O. Gastroenterologist Regional Gastroenterology INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is characterized by
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationEASL-EASD-EASO Clinical Practice Guidelines for the management and treatment of NAFLD. Francesco Negro University of Geneva - Switzerland
EASL-EASD-EASO Clinical Practice Guidelines for the management and treatment of NAFLD Francesco Negro University of Geneva - Switzerland EASL EASD - EASO G Marchesini CP Day J-F Dufour A Canbay V Nobili
More informationTreatment of Non-Alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease Treatment of Non-Alcoholic Fatty Liver Disease Antonia Scherer a, b Jean-François Dufour a, b a Department of Clinical Research, Hepatology, and b University Clinic for
More informationAgenda. Case #2: Progression of Liver Disease. Time Presenter Topic. 6:45 7:00 Registration Registration/Seating
Agenda Time Presenter Topic 6:45 7:00 Registration Registration/Seating 7:00 7:10 Dr. Younossi 7:10 7:30 Dr. Ratziu Welcome & Introduction to Epidemiology of NAFLD Recent Advances in the Diagnosis, Management
More informationParis Hepatology Conference PROGNOSIS OF NASH
Paris Hepatology Conference PROGNOSIS OF NASH Palais des Congrès Monday 15th January 2018 14:45-15:00 PHC 2018 - www.aphc.info Driven to care Disclosures Advisory committees Speaking and teaching Research
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationVolixibat for non-alcoholic steatohepatitis (NASH)
NIHR Innovation Observatory Evidence Briefing: October 2017 Volixibat for non-alcoholic steatohepatitis (NASH) NIHRIO (HSRIC) ID: 10240 NICE ID: 9524 LAY SUMMARY Non-alcoholic steatohepatitis (NASH) is
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More information